Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease

被引:15
|
作者
Hawkins, Nathaniel M. [1 ,7 ]
Nordon, Clementine [2 ]
Rhodes, Kirsty [2 ]
Talukdar, Manisha [3 ]
Mcmullen, Suzanne [4 ]
Ekwaru, Paul [4 ]
Pham, Tram [4 ]
Randhawa, Arsh K. [3 ]
Sin, Don D. [5 ,6 ]
机构
[1] Univ British Columbia, Ctr Cardiovasc Innovat, Div Cardiol, Vancouver, BC, Canada
[2] AstraZeneca UK Ltd, Cambridge, England
[3] AstraZeneca Canada Inc, Mississauga, ON, Canada
[4] Medlior Hlth Outcomes Res Ltd, Calgary, AB, Canada
[5] Univ British Columbia, UBC Ctr Heart Lung Innovat, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Med Respirol, Vancouver, BC, Canada
[7] Univ British Columbia, St Pauls Hosp, Cardiol, 1081 Burrard St, Vancouver, BC, Canada
关键词
Heart Failure; Arrhythmias; Cardiac; Risk Factors; HEART-FAILURE; COPD; INFLAMMATION; STROKE;
D O I
10.1136/heartjnl-2023-323487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo examine the risk of adverse cardiovascular (CV) events following an exacerbation of chronic obstructive pulmonary disease (COPD).MethodsThis retrospective cohort study identified patients with COPD using administrative data from Alberta, Canada from 2014 to 2019. Exposure periods were 12 months following moderate or severe exacerbations; the reference period was time preceding a first exacerbation. The primary outcome was the composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia. Time-dependent Cox regression models estimated covariate-adjusted risks associated with six exposure subperiods following exacerbation.ResultsAmong 1 42 787 patients (mean age 68.1 years and 51.7% men) 61 981 (43.4%) experienced at least one exacerbation and 34 068 (23.9%) died during median follow-up of 64 months. The primary outcome occurred in 43 564 (30.5%) patients with an incidence rate prior to exacerbation of 5.43 (95% CI 5.36 to 5.50) per 100 person-years. This increased to 95.61 per 100 person-years in the 1-7 days postexacerbation (adjusted HR 15.86, 95% CI 15.17 to 16.58) and remained increased for up to 1 year. The risk of both the composite and individual CV events was increased following either a moderate or a severe exacerbation, though greater and more prolonged following severe exacerbation. The highest magnitude of increased risk was observed for HF decompensation (1-7 days, HR 72.34, 95% CI 64.43 to 81.22).ConclusionModerate and severe COPD exacerbations are independent risk factors for adverse CV events, especially HF decompensation. The impact of optimising COPD management on CV outcomes should be evaluated.
引用
收藏
页码:702 / 709
页数:8
相关论文
共 50 条
  • [41] Cardiopulmonary interactions: Cardiovascular diseases and chronic obstructive pulmonary disease
    Ukena, C.
    Kindermann, M.
    Mahfoud, F.
    Kindermann, I.
    Boehm, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2009, 134 (16) : 818 - 822
  • [42] Chronic obstructive pulmonary disease and cardiovascular co-morbidities
    Panuccio, Domenico
    Giusti, Massimo
    ITALIAN JOURNAL OF MEDICINE, 2008, 2 (03) : 42 - 46
  • [43] Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases
    Deshmukh, Kartik
    Khanna, Arjun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2021, 84 (01) : 35 - 45
  • [44] Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction
    Chiung-Hung Lin
    Jih-Kai Yeh
    Ting-Yu Lin
    Yu-Lun Lo
    Bo-Jui Chang
    Jia-Shiuan Ju
    Tzu-Hsuan Chiu
    Pi-Hung Tung
    Yun-Ju Huang
    Shu-Min Lin
    BMC Pulmonary Medicine, 23
  • [45] Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease
    Brusse-Keizer, Marjolein
    van der Palen, Job
    van der Valk, Paul
    Hendrix, Ron
    Kerstjens, Huib
    CLINICAL RESPIRATORY JOURNAL, 2011, 5 (04) : 227 - 234
  • [46] Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease
    Onishi, Katsuya
    JOURNAL OF CARDIOLOGY, 2017, 70 (1-2) : 128 - 134
  • [47] The Role of Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease
    Macrea, Madalina
    Coleman, John M., III
    MEDICAL CLINICS OF NORTH AMERICA, 2022, 106 (06) : 961 - 969
  • [48] Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction
    Lin, Chiung-Hung
    Yeh, Jih-Kai
    Lin, Ting-Yu
    Lo, Yu-Lun
    Chang, Bo-Jui
    Ju, Jia-Shiuan
    Chiu, Tzu-Hsuan
    Tung, Pi-Hung
    Huang, Yun-Ju
    Lin, Shu-Min
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [49] Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease
    Viglino, Damien
    Plazanet, Anais
    Bailly, Sebastien
    Benmerad, Meriem
    Jullian-Desayes, Ingrid
    Tamisier, Renaud
    Leroy, Vincent
    Zarski, Jean-Pierre
    Maignan, Maxime
    Joyeux-Faure, Marie
    Pepin, Jean-Louis
    SCIENTIFIC REPORTS, 2018, 8
  • [50] Outcome of pulmonary rehabilitation in patients after acute exacerbation of chronic obstructive pulmonary disease
    Deepak, T. H.
    Mohapatra, Prasanta
    Janmeja, Ashok
    Sood, Parul
    Gupta, Monika
    Aggarwal, Deepak
    Prashanth, C.
    Gupta, Robin
    Katyal, Rahul
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42